Build the case before submission
Research label precedent, assess safety signals, and shape regulatory narratives with evidence in one workflow.
Precedent, endpoints, and risk in one view
See how EMET supports regulatory affairs teams focused on safety assessment, label precedent, and regulatory strategy.
Regulatory affairs capabilities
Explore a range of sample prompts and representative outputs from EMET across the workflows below.
Published Safety Signal Detection
Run a pharmacovigilance assessment for ibrutinib. Identify the top adverse event signals and classify the overall risk level.
Label Precedent Research
Compare the approved indications and boxed warnings across all approved BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib). I need precedent labeling language for a new BTK inhibitor CLL submission.
Trial Landscape Intelligence
Map the Phase 2/3 clinical trial landscape for KRAS G12C inhibitors in NSCLC. What endpoints are sponsors using and what has regulatory precedent?
Benefit-Risk Synthesis
Synthesise the benefit-risk case for a TROP2 ADC in HR+/HER2-low metastatic breast cancer for our regulatory strategy narrative.
Patent FTO Screening
Screen for active blocking patents on covalent EGFR exon 20 insertion inhibitors. Flag key assignees and provide an FTO assessment.
Frequently asked questions
Drug programs fail when biology is misunderstood. EMET exists to close that gap — before it closes your pipeline.
Start free trial